-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical News, May 31st, in recent years, with the development of society and the improvement of living consumption levels, women's health awareness has gradually increased, and the gynecological Chinese patent medicine market has also attracted much attention.
The latest data from Minai.
com shows that in 2020, the market of Chinese public medical institutions' terminal gynecological patent medicines will be affected by the epidemic, and sales will decline year-on-year.
Judging from the sales structure of manufacturers, Zhuzhou Qianjin Pharmaceutical, Shandong Buchang Shenzhou Pharmaceutical, Guiyang Xintian Pharmaceutical, Hainan Bikai Pharmaceutical, and Jiangsu Kangyuan Pharmaceutical rank in the top five.
Among the TOP10 products, 9 are exclusive.
The market share of Gynecological Qianjin Capsules is increasing, and Kuntai Capsules and Zishen Yutai Pills have grown against the trend.
In terms of quantity, Shandong Buchang Shenzhou Pharmaceutical has the most products, with two products in the TOP10 Medium; From the perspective of treatment categories, there are 5 drugs for gynecological inflammation.
The latest data from Minai.
com shows that in 2020, the market of Chinese public medical institutions' terminal gynecological patent medicines will be affected by the epidemic, and sales will decline year-on-year.
Judging from the sales structure of manufacturers, Zhuzhou Qianjin Pharmaceutical, Shandong Buchang Shenzhou Pharmaceutical, Guiyang Xintian Pharmaceutical, Hainan Bikai Pharmaceutical, and Jiangsu Kangyuan Pharmaceutical rank in the top five.
Among the TOP10 products, 9 are exclusive.
The market share of Gynecological Qianjin Capsules is increasing, and Kuntai Capsules and Zishen Yutai Pills have grown against the trend.
In terms of quantity, Shandong Buchang Shenzhou Pharmaceutical has the most products, with two products in the TOP10 Medium; From the perspective of treatment categories, there are 5 drugs for gynecological inflammation.
TOP10 Chinese patent medicines for gynecology ! Daughter, step length, health.
.
.
9 exclusive products are eye-catching
.
.
9 exclusive products are eye-catching
Sales of Chinese patent medicines for gynecology in public medical institutions in China in recent years
Source: Terminal competition landscape of China's public medical institutions
According to data from Menet.
com, in 2020, the market of Chinese public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) terminal gynecological Chinese patent medicines has been affected by the epidemic, and sales have declined year-on-year.
From the perspective of quarterly sales trends, compared with the first half of 2020, the market is picking up in the second half of the year.
From the perspective of sales channels, the market share of urban public hospitals and urban community centers has increased.
From the perspective of the manufacturer's sales structure, Zhuzhou Qianjin Pharmaceutical, Shandong Buchang Shenzhou Pharmaceutical, Guiyang Xintian Pharmaceutical, Hainan Bikai Pharmaceutical, and Jiangsu Kangyuan Pharmaceutical rank in the top five, with a combined market share of more than 20%.
com, in 2020, the market of Chinese public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) terminal gynecological Chinese patent medicines has been affected by the epidemic, and sales have declined year-on-year.
From the perspective of quarterly sales trends, compared with the first half of 2020, the market is picking up in the second half of the year.
From the perspective of sales channels, the market share of urban public hospitals and urban community centers has increased.
From the perspective of the manufacturer's sales structure, Zhuzhou Qianjin Pharmaceutical, Shandong Buchang Shenzhou Pharmaceutical, Guiyang Xintian Pharmaceutical, Hainan Bikai Pharmaceutical, and Jiangsu Kangyuan Pharmaceutical rank in the top five, with a combined market share of more than 20%.
2020 Top 10 Chinese Patented Gynecological Products in Public Medical Institutions in China
Source: Terminal competition landscape of China's public medical institutions
Among the TOP10 products, 9 are exclusive, involving 8 companies including Zhuzhou Qianjin Pharmaceutical, Shandong Buchang Shenzhou Pharmaceutical, Jiangsu Kangyuan Pharmaceutical, etc.
The market share of Gynecological Qianjin Capsules is increasing, Kuntai Capsules, Zishen Yutai Pills Growth against the trend.
In terms of quantity, Shandong Buchang Shenzhou Pharmaceutical has the most, and Honghe Fujie Lotion and Kangfuyan Capsules are among the TOP10 products.
From the perspective of treatment categories, there are 5 drugs used for gynecological inflammation.
The market share of Gynecological Qianjin Capsules is increasing, Kuntai Capsules, Zishen Yutai Pills Growth against the trend.
In terms of quantity, Shandong Buchang Shenzhou Pharmaceutical has the most, and Honghe Fujie Lotion and Kangfuyan Capsules are among the TOP10 products.
From the perspective of treatment categories, there are 5 drugs used for gynecological inflammation.
The market share of Gynecological Qianjin Capsules is increasing, and the two major products of Step Length occupy the top ten
Market share of terminal gynecological Qianjin capsules in China's public medical institutions in recent years
Source: Terminal competition landscape of China's public medical institutions
Gynecological Qianjin Capsule is the exclusive product of Zhuzhou Qianjin Pharmaceutical.
According to data from Mi Nei.
com, the market share of terminal gynecological Qianjin capsules in China's public medical institutions has steadily increased in recent years, and the market share will reach 3.
34% in 2020.
Qianjin Pharmaceutical pointed out in its annual report that the company’s products are mainly sold through medical terminals and retail terminals.
The medical marketing department has been established in the hospital terminal company to actively participate in national and provincial and municipal medical academic seminars to disseminate and exchange the company’s products.
The clinical research results enable professional doctors to understand, be familiar with and recognize the characteristics and efficacy of the company's products, thereby ensuring the clinical and rational use of the products, and ultimately transforming product advantages into market advantages.
With the advancement of the national basic medicine policy, the company implements the marketing strategy of "basic medicine development", focusing on promoting the two exclusive basic medicine products of gynecological Qianjin tablets/capsules and Buxueyimu pills/granules.
Under the influence of the epidemic, the medical sector A certain share of growth has been maintained throughout the year.
It is worth mentioning that Gynecological Qianjin Tablets/Capsules have maintained the status of the first brand of oral gynecological inflammation Chinese patent medicine for more than ten consecutive years.
According to data from Mi Nei.
com, the market share of terminal gynecological Qianjin capsules in China's public medical institutions has steadily increased in recent years, and the market share will reach 3.
34% in 2020.
Qianjin Pharmaceutical pointed out in its annual report that the company’s products are mainly sold through medical terminals and retail terminals.
The medical marketing department has been established in the hospital terminal company to actively participate in national and provincial and municipal medical academic seminars to disseminate and exchange the company’s products.
The clinical research results enable professional doctors to understand, be familiar with and recognize the characteristics and efficacy of the company's products, thereby ensuring the clinical and rational use of the products, and ultimately transforming product advantages into market advantages.
With the advancement of the national basic medicine policy, the company implements the marketing strategy of "basic medicine development", focusing on promoting the two exclusive basic medicine products of gynecological Qianjin tablets/capsules and Buxueyimu pills/granules.
Under the influence of the epidemic, the medical sector A certain share of growth has been maintained throughout the year.
It is worth mentioning that Gynecological Qianjin Tablets/Capsules have maintained the status of the first brand of oral gynecological inflammation Chinese patent medicine for more than ten consecutive years.
The market share of Honghe Fujie Lotion and Kangfuyan Capsules in China's public medical institutions in recent years
Source: Terminal competition landscape of China's public medical institutions
According to data from Minai.
com, in 2020, the two exclusive products of Shandong Buchang Shenzhou Pharmaceutical, the terminal of China's public medical institutions, Honghe Fujie Lotion and Kangfuyan Capsules are both in the TOP10 products.
In recent years, Buchang Pharmaceuticals has focused on increasing the development of new products in the treatment of cardio-cerebrovascular, gynecology, diabetes and other major diseases.
Among them, it has continued to develop products such as Honghe Fujie Lotion and Kangfuyan Capsules.
Exploit the potential of existing products and extend the product life cycle.
com, in 2020, the two exclusive products of Shandong Buchang Shenzhou Pharmaceutical, the terminal of China's public medical institutions, Honghe Fujie Lotion and Kangfuyan Capsules are both in the TOP10 products.
In recent years, Buchang Pharmaceuticals has focused on increasing the development of new products in the treatment of cardio-cerebrovascular, gynecology, diabetes and other major diseases.
Among them, it has continued to develop products such as Honghe Fujie Lotion and Kangfuyan Capsules.
Exploit the potential of existing products and extend the product life cycle.
Kuntai Capsules and Zishen Yutai Pills grow against the trend
Sales of Kuntai Capsules in Public Medical Institutions in China in Recent Years
Source: Terminal competition landscape of China's public medical institutions
Kuntai Capsule is an exclusive product of Guiyang Xintian Pharmaceutical.
It is a pure Chinese medicine patented product for the improvement of clinical symptoms related to "ovarian function decline" (including improvement of clinical symptoms related to menopausal syndrome).
According to data from Mi Nei.
com, the sales of Kuntai capsules in China's public medical institutions have grown steadily in recent years, with a year-on-year growth of 9.
09% in 2020, ranking it among the top 3 products.
Xintian Pharmaceutical said that Kuntai Capsule is one of the company's main varieties of rapid development in the future.
In addition, the company will further use its brand advantages to continuously strengthen the marketing of exclusive varieties such as Kuntai capsules and Sophora flavescens gel to expand market share; make full use of the company's industry advantages to continuously attract outstanding talents in scientific and technological innovation , and promote industrial and product innovation; At the same time, it takes advantage of the company's capital to actively carry out high-quality industry investment and mergers and acquisitions.
Through multiple measures to promote the continuous growth of the company's performance, and continuously improve the company's overall industry position and market competitiveness.
It is a pure Chinese medicine patented product for the improvement of clinical symptoms related to "ovarian function decline" (including improvement of clinical symptoms related to menopausal syndrome).
According to data from Mi Nei.
com, the sales of Kuntai capsules in China's public medical institutions have grown steadily in recent years, with a year-on-year growth of 9.
09% in 2020, ranking it among the top 3 products.
Xintian Pharmaceutical said that Kuntai Capsule is one of the company's main varieties of rapid development in the future.
In addition, the company will further use its brand advantages to continuously strengthen the marketing of exclusive varieties such as Kuntai capsules and Sophora flavescens gel to expand market share; make full use of the company's industry advantages to continuously attract outstanding talents in scientific and technological innovation , and promote industrial and product innovation; At the same time, it takes advantage of the company's capital to actively carry out high-quality industry investment and mergers and acquisitions.
Through multiple measures to promote the continuous growth of the company's performance, and continuously improve the company's overall industry position and market competitiveness.
Sales of Terminal Zishen Yutai Pills in China's Public Medical Institutions in Recent Years
Source: Terminal competition landscape of China's public medical institutions
Zishen Yutai Pills is an exclusive product of Guangzhou Baiyunshan Zhongyi Pharmaceutical.
It is used for slippery fetus caused by deficiency of both spleen and kidney and inconsistent treatment (prevention and treatment of habitual abortion and threatened abortion).
According to data from Mi Nei.
com, the sales of terminal Zishen Yutai pills in public medical institutions in China have grown rapidly in recent years.
In 2019, they increased by more than 80% year-on-year, and again by 8.
55% in 2020.
The market share has also risen from 1.
07% in 2018 to 2020.
2.
64% of the total.
Baiyunshan's analysis of the production and sales of main products in the 2020 annual report pointed out that the inventory of Zishen Yutai Pills increased significantly year-on-year, mainly due to the expected increase in product sales demand by the subordinate production enterprises , and the inventory was prepared in advance.
It is worth mentioning that the sales volume of Zishen Yutai Pills in 2019 increased by more than 60% year-on-year, mainly due to increased investment in product design, R&D and marketing in the early stage, and with the liberalization of the national two-child policy, products entered During the period of rapid development, the sales volume increased rapidly.
It is used for slippery fetus caused by deficiency of both spleen and kidney and inconsistent treatment (prevention and treatment of habitual abortion and threatened abortion).
According to data from Mi Nei.
com, the sales of terminal Zishen Yutai pills in public medical institutions in China have grown rapidly in recent years.
In 2019, they increased by more than 80% year-on-year, and again by 8.
55% in 2020.
The market share has also risen from 1.
07% in 2018 to 2020.
2.
64% of the total.
Baiyunshan's analysis of the production and sales of main products in the 2020 annual report pointed out that the inventory of Zishen Yutai Pills increased significantly year-on-year, mainly due to the expected increase in product sales demand by the subordinate production enterprises , and the inventory was prepared in advance.
It is worth mentioning that the sales volume of Zishen Yutai Pills in 2019 increased by more than 60% year-on-year, mainly due to increased investment in product design, R&D and marketing in the early stage, and with the liberalization of the national two-child policy, products entered During the period of rapid development, the sales volume increased rapidly.
Source: Mi Nei.
com database, announcement of listed companies
com database, announcement of listed companies
Medical News, May 31st, in recent years, with the development of society and the improvement of living consumption levels, women's health awareness has gradually increased, and the gynecological Chinese patent medicine market has also attracted much attention.
The latest data from Minai.
com shows that in 2020, the market of Chinese public medical institutions' terminal gynecological patent medicines will be affected by the epidemic, and sales will decline year-on-year.
Judging from the sales structure of manufacturers, Zhuzhou Qianjin Pharmaceutical, Shandong Buchang Shenzhou Pharmaceutical, Guiyang Xintian Pharmaceutical, Hainan Bikai Pharmaceutical, and Jiangsu Kangyuan Pharmaceutical rank in the top five.
Among the TOP10 products, 9 are exclusive.
The market share of Gynecological Qianjin Capsules is increasing, and Kuntai Capsules and Zishen Yutai Pills have grown against the trend.
In terms of quantity, Shandong Buchang Shenzhou Pharmaceutical has the most products, with two products in the TOP10 Medium; From the perspective of treatment categories, there are 5 drugs for gynecological inflammation.
The latest data from Minai.
com shows that in 2020, the market of Chinese public medical institutions' terminal gynecological patent medicines will be affected by the epidemic, and sales will decline year-on-year.
Judging from the sales structure of manufacturers, Zhuzhou Qianjin Pharmaceutical, Shandong Buchang Shenzhou Pharmaceutical, Guiyang Xintian Pharmaceutical, Hainan Bikai Pharmaceutical, and Jiangsu Kangyuan Pharmaceutical rank in the top five.
Among the TOP10 products, 9 are exclusive.
The market share of Gynecological Qianjin Capsules is increasing, and Kuntai Capsules and Zishen Yutai Pills have grown against the trend.
In terms of quantity, Shandong Buchang Shenzhou Pharmaceutical has the most products, with two products in the TOP10 Medium; From the perspective of treatment categories, there are 5 drugs for gynecological inflammation.
TOP10 Chinese patent medicines for gynecology ! Daughter, step length, health.
.
.
9 exclusive products are eye-catching
.
.
9 exclusive products are eye-catching
Sales of Chinese patent medicines for gynecology in public medical institutions in China in recent years
Source: Terminal competition landscape of China's public medical institutions
According to data from Menet.
com, in 2020, the market of Chinese public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) terminal gynecological Chinese patent medicines has been affected by the epidemic, and sales have declined year-on-year.
From the perspective of quarterly sales trends, compared with the first half of 2020, the market is picking up in the second half of the year.
From the perspective of sales channels, the market share of urban public hospitals and urban community centers has increased.
From the perspective of the manufacturer's sales structure, Zhuzhou Qianjin Pharmaceutical, Shandong Buchang Shenzhou Pharmaceutical, Guiyang Xintian Pharmaceutical, Hainan Bikai Pharmaceutical, and Jiangsu Kangyuan Pharmaceutical rank in the top five, with a combined market share of more than 20%.
com, in 2020, the market of Chinese public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) terminal gynecological Chinese patent medicines has been affected by the epidemic, and sales have declined year-on-year.
From the perspective of quarterly sales trends, compared with the first half of 2020, the market is picking up in the second half of the year.
From the perspective of sales channels, the market share of urban public hospitals and urban community centers has increased.
From the perspective of the manufacturer's sales structure, Zhuzhou Qianjin Pharmaceutical, Shandong Buchang Shenzhou Pharmaceutical, Guiyang Xintian Pharmaceutical, Hainan Bikai Pharmaceutical, and Jiangsu Kangyuan Pharmaceutical rank in the top five, with a combined market share of more than 20%.
2020 Top 10 Chinese Patented Gynecological Products in Public Medical Institutions in China
Source: Terminal competition landscape of China's public medical institutions
Among the TOP10 products, 9 are exclusive, involving 8 companies including Zhuzhou Qianjin Pharmaceutical, Shandong Buchang Shenzhou Pharmaceutical, Jiangsu Kangyuan Pharmaceutical, etc.
The market share of Gynecological Qianjin Capsules is increasing, Kuntai Capsules, Zishen Yutai Pills Growth against the trend.
In terms of quantity, Shandong Buchang Shenzhou Pharmaceutical has the most, and Honghe Fujie Lotion and Kangfuyan Capsules are among the TOP10 products.
From the perspective of treatment categories, there are 5 drugs used for gynecological inflammation.
The market share of Gynecological Qianjin Capsules is increasing, Kuntai Capsules, Zishen Yutai Pills Growth against the trend.
In terms of quantity, Shandong Buchang Shenzhou Pharmaceutical has the most, and Honghe Fujie Lotion and Kangfuyan Capsules are among the TOP10 products.
From the perspective of treatment categories, there are 5 drugs used for gynecological inflammation.
The market share of Gynecological Qianjin Capsules is increasing, and the two major products of Step Length occupy the top ten
Market share of terminal gynecological Qianjin capsules in China's public medical institutions in recent years
Source: Terminal competition landscape of China's public medical institutions
Gynecological Qianjin Capsule is the exclusive product of Zhuzhou Qianjin Pharmaceutical.
According to data from Mi Nei.
com, the market share of terminal gynecological Qianjin capsules in China's public medical institutions has steadily increased in recent years, and the market share will reach 3.
34% in 2020.
Qianjin Pharmaceutical pointed out in its annual report that the company’s products are mainly sold through medical terminals and retail terminals.
The medical marketing department has been established in the hospital terminal company to actively participate in national and provincial and municipal medical academic seminars to disseminate and exchange the company’s products.
The clinical research results enable professional doctors to understand, be familiar with and recognize the characteristics and efficacy of the company's products, thereby ensuring the clinical and rational use of the products, and ultimately transforming product advantages into market advantages.
With the advancement of the national basic medicine policy, the company implements the marketing strategy of "basic medicine development", focusing on promoting the two exclusive basic medicine products of gynecological Qianjin tablets/capsules and Buxueyimu pills/granules.
Under the influence of the epidemic, the medical sector A certain share of growth has been maintained throughout the year.
It is worth mentioning that Gynecological Qianjin Tablets/Capsules have maintained the status of the first brand of oral gynecological inflammation Chinese patent medicine for more than ten consecutive years.
According to data from Mi Nei.
com, the market share of terminal gynecological Qianjin capsules in China's public medical institutions has steadily increased in recent years, and the market share will reach 3.
34% in 2020.
Qianjin Pharmaceutical pointed out in its annual report that the company’s products are mainly sold through medical terminals and retail terminals.
The medical marketing department has been established in the hospital terminal company to actively participate in national and provincial and municipal medical academic seminars to disseminate and exchange the company’s products.
The clinical research results enable professional doctors to understand, be familiar with and recognize the characteristics and efficacy of the company's products, thereby ensuring the clinical and rational use of the products, and ultimately transforming product advantages into market advantages.
With the advancement of the national basic medicine policy, the company implements the marketing strategy of "basic medicine development", focusing on promoting the two exclusive basic medicine products of gynecological Qianjin tablets/capsules and Buxueyimu pills/granules.
Under the influence of the epidemic, the medical sector A certain share of growth has been maintained throughout the year.
It is worth mentioning that Gynecological Qianjin Tablets/Capsules have maintained the status of the first brand of oral gynecological inflammation Chinese patent medicine for more than ten consecutive years.
The market share of Honghe Fujie Lotion and Kangfuyan Capsules in China's public medical institutions in recent years
Source: Terminal competition landscape of China's public medical institutions
According to data from Minai.
com, in 2020, the two exclusive products of Shandong Buchang Shenzhou Pharmaceutical, the terminal of China's public medical institutions, Honghe Fujie Lotion and Kangfuyan Capsules are both in the TOP10 products.
In recent years, Buchang Pharmaceuticals has focused on increasing the development of new products in the treatment of cardio-cerebrovascular, gynecology, diabetes and other major diseases.
Among them, it has continued to develop products such as Honghe Fujie Lotion and Kangfuyan Capsules.
Exploit the potential of existing products and extend the product life cycle.
com, in 2020, the two exclusive products of Shandong Buchang Shenzhou Pharmaceutical, the terminal of China's public medical institutions, Honghe Fujie Lotion and Kangfuyan Capsules are both in the TOP10 products.
In recent years, Buchang Pharmaceuticals has focused on increasing the development of new products in the treatment of cardio-cerebrovascular, gynecology, diabetes and other major diseases.
Among them, it has continued to develop products such as Honghe Fujie Lotion and Kangfuyan Capsules.
Exploit the potential of existing products and extend the product life cycle.
Kuntai Capsules and Zishen Yutai Pills grow against the trend
Sales of Kuntai Capsules in Public Medical Institutions in China in Recent Years
Source: Terminal competition landscape of China's public medical institutions
Kuntai Capsule is an exclusive product of Guiyang Xintian Pharmaceutical.
It is a pure Chinese medicine patented product for the improvement of clinical symptoms related to "ovarian function decline" (including improvement of clinical symptoms related to menopausal syndrome).
According to data from Mi Nei.
com, the sales of Kuntai capsules in China's public medical institutions have grown steadily in recent years, with a year-on-year growth of 9.
09% in 2020, ranking it among the top 3 products.
Xintian Pharmaceutical said that Kuntai Capsule is one of the company's main varieties of rapid development in the future.
In addition, the company will further use its brand advantages to continuously strengthen the marketing of exclusive varieties such as Kuntai capsules and Sophora flavescens gel to expand market share; make full use of the company's industry advantages to continuously attract outstanding talents in scientific and technological innovation , and promote industrial and product innovation; At the same time, it takes advantage of the company's capital to actively carry out high-quality industry investment and mergers and acquisitions.
Through multiple measures to promote the continuous growth of the company's performance, and continuously improve the company's overall industry position and market competitiveness.
It is a pure Chinese medicine patented product for the improvement of clinical symptoms related to "ovarian function decline" (including improvement of clinical symptoms related to menopausal syndrome).
According to data from Mi Nei.
com, the sales of Kuntai capsules in China's public medical institutions have grown steadily in recent years, with a year-on-year growth of 9.
09% in 2020, ranking it among the top 3 products.
Xintian Pharmaceutical said that Kuntai Capsule is one of the company's main varieties of rapid development in the future.
In addition, the company will further use its brand advantages to continuously strengthen the marketing of exclusive varieties such as Kuntai capsules and Sophora flavescens gel to expand market share; make full use of the company's industry advantages to continuously attract outstanding talents in scientific and technological innovation , and promote industrial and product innovation; At the same time, it takes advantage of the company's capital to actively carry out high-quality industry investment and mergers and acquisitions.
Through multiple measures to promote the continuous growth of the company's performance, and continuously improve the company's overall industry position and market competitiveness.
Sales of Terminal Zishen Yutai Pills in China's Public Medical Institutions in Recent Years
Source: Terminal competition landscape of China's public medical institutions
Zishen Yutai Pills is an exclusive product of Guangzhou Baiyunshan Zhongyi Pharmaceutical.
It is used for slippery fetus caused by deficiency of both spleen and kidney and inconsistent treatment (prevention and treatment of habitual abortion and threatened abortion).
According to data from Mi Nei.
com, the sales of terminal Zishen Yutai pills in public medical institutions in China have grown rapidly in recent years.
In 2019, they increased by more than 80% year-on-year, and again by 8.
55% in 2020.
The market share has also risen from 1.
07% in 2018 to 2020.
2.
64% of the total.
Baiyunshan's analysis of the production and sales of main products in the 2020 annual report pointed out that the inventory of Zishen Yutai Pills increased significantly year-on-year, mainly due to the expected increase in product sales demand by the subordinate production enterprises , and the inventory was prepared in advance.
It is worth mentioning that the sales volume of Zishen Yutai Pills in 2019 increased by more than 60% year-on-year, mainly due to increased investment in product design, R&D and marketing in the early stage, and with the liberalization of the national two-child policy, products entered During the period of rapid development, the sales volume increased rapidly.
It is used for slippery fetus caused by deficiency of both spleen and kidney and inconsistent treatment (prevention and treatment of habitual abortion and threatened abortion).
According to data from Mi Nei.
com, the sales of terminal Zishen Yutai pills in public medical institutions in China have grown rapidly in recent years.
In 2019, they increased by more than 80% year-on-year, and again by 8.
55% in 2020.
The market share has also risen from 1.
07% in 2018 to 2020.
2.
64% of the total.
Baiyunshan's analysis of the production and sales of main products in the 2020 annual report pointed out that the inventory of Zishen Yutai Pills increased significantly year-on-year, mainly due to the expected increase in product sales demand by the subordinate production enterprises , and the inventory was prepared in advance.
It is worth mentioning that the sales volume of Zishen Yutai Pills in 2019 increased by more than 60% year-on-year, mainly due to increased investment in product design, R&D and marketing in the early stage, and with the liberalization of the national two-child policy, products entered During the period of rapid development, the sales volume increased rapidly.
Source: Mi Nei.
com database, announcement of listed companies
com database, announcement of listed companies
Medical News, May 31st, in recent years, with the development of society and the improvement of living consumption levels, women's health awareness has gradually increased, and the gynecological Chinese patent medicine market has also attracted much attention.
The latest data from Minai.
com shows that in 2020, the market of Chinese public medical institutions' terminal gynecological patent medicines will be affected by the epidemic, and sales will decline year-on-year.
Judging from the sales structure of manufacturers, Zhuzhou Qianjin Pharmaceutical, Shandong Buchang Shenzhou Pharmaceutical, Guiyang Xintian Pharmaceutical, Hainan Bikai Pharmaceutical, and Jiangsu Kangyuan Pharmaceutical rank in the top five.
Among the TOP10 products, 9 are exclusive.
The market share of Gynecological Qianjin Capsules is increasing, and Kuntai Capsules and Zishen Yutai Pills have grown against the trend.
In terms of quantity, Shandong Buchang Shenzhou Pharmaceutical has the most products, with two products in the TOP10 Medium; From the perspective of treatment categories, there are 5 drugs for gynecological inflammation.
The latest data from Minai.
com shows that in 2020, the market of Chinese public medical institutions' terminal gynecological patent medicines will be affected by the epidemic, and sales will decline year-on-year.
Judging from the sales structure of manufacturers, Zhuzhou Qianjin Pharmaceutical, Shandong Buchang Shenzhou Pharmaceutical, Guiyang Xintian Pharmaceutical, Hainan Bikai Pharmaceutical, and Jiangsu Kangyuan Pharmaceutical rank in the top five.
Among the TOP10 products, 9 are exclusive.
The market share of Gynecological Qianjin Capsules is increasing, and Kuntai Capsules and Zishen Yutai Pills have grown against the trend.
In terms of quantity, Shandong Buchang Shenzhou Pharmaceutical has the most products, with two products in the TOP10 Medium; From the perspective of treatment categories, there are 5 drugs for gynecological inflammation.
TOP10 Chinese patent medicines for gynecology ! Daughter, step length, health.
.
.
9 exclusive products are eye-catching
TOP10 Chinese patent medicines for gynecology ! Daughter, step length, health. .
.
9 exclusive products are eye-catching
.
.
9 exclusive products are eye-catching
Sales of Chinese patent medicines for gynecology in public medical institutions in China in recent years
Source: Terminal competition landscape of China's public medical institutions
According to data from Menet.
com, in 2020, the market of Chinese public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) terminal gynecological Chinese patent medicines has been affected by the epidemic, and sales have declined year-on-year.
From the perspective of quarterly sales trends, compared with the first half of 2020, the market is picking up in the second half of the year.
From the perspective of sales channels, the market share of urban public hospitals and urban community centers has increased.
From the perspective of the manufacturer's sales structure, Zhuzhou Qianjin Pharmaceutical, Shandong Buchang Shenzhou Pharmaceutical, Guiyang Xintian Pharmaceutical, Hainan Bikai Pharmaceutical, and Jiangsu Kangyuan Pharmaceutical rank in the top five, with a combined market share of more than 20%.
Hospital hospital hospitalcom, in 2020, the market of Chinese public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) terminal gynecological Chinese patent medicines has been affected by the epidemic, and sales have declined year-on-year.
From the perspective of quarterly sales trends, compared with the first half of 2020, the market is picking up in the second half of the year.
From the perspective of sales channels, the market share of urban public hospitals and urban community centers has increased.
From the perspective of the manufacturer's sales structure, Zhuzhou Qianjin Pharmaceutical, Shandong Buchang Shenzhou Pharmaceutical, Guiyang Xintian Pharmaceutical, Hainan Bikai Pharmaceutical, and Jiangsu Kangyuan Pharmaceutical rank in the top five, with a combined market share of more than 20%.
2020 Top 10 Chinese Patented Gynecological Products in Public Medical Institutions in China
Source: Terminal competition landscape of China's public medical institutions
Among the TOP10 products, 9 are exclusive, involving 8 companies including Zhuzhou Qianjin Pharmaceutical, Shandong Buchang Shenzhou Pharmaceutical, Jiangsu Kangyuan Pharmaceutical, etc.
The market share of Gynecological Qianjin Capsules is increasing, Kuntai Capsules, Zishen Yutai Pills Growth against the trend.
In terms of quantity, Shandong Buchang Shenzhou Pharmaceutical has the most, and Honghe Fujie Lotion and Kangfuyan Capsules are among the TOP10 products.
From the perspective of treatment categories, there are 5 drugs used for gynecological inflammation.
The market share of Gynecological Qianjin Capsules is increasing, Kuntai Capsules, Zishen Yutai Pills Growth against the trend.
In terms of quantity, Shandong Buchang Shenzhou Pharmaceutical has the most, and Honghe Fujie Lotion and Kangfuyan Capsules are among the TOP10 products.
From the perspective of treatment categories, there are 5 drugs used for gynecological inflammation.
The market share of Gynecological Qianjin Capsules is increasing, and the two major products of Step Length occupy the top ten
The market share of Gynecological Qianjin Capsules is increasing, and the two major products of Step Length occupy the top ten Market share of terminal gynecological Qianjin capsules in China's public medical institutions in recent years
Source: Terminal competition landscape of China's public medical institutions
Gynecological Qianjin Capsule is the exclusive product of Zhuzhou Qianjin Pharmaceutical.
According to data from Mi Nei.
com, the market share of terminal gynecological Qianjin capsules in China's public medical institutions has steadily increased in recent years, and the market share will reach 3.
34% in 2020.
Qianjin Pharmaceutical pointed out in its annual report that the company’s products are mainly sold through medical terminals and retail terminals.
The medical marketing department has been established in the hospital terminal company to actively participate in national and provincial and municipal medical academic seminars to disseminate and exchange the company’s products.
The clinical research results enable professional doctors to understand, be familiar with and recognize the characteristics and efficacy of the company's products, thereby ensuring the clinical and rational use of the products, and ultimately transforming product advantages into market advantages.
With the advancement of the national basic medicine policy, the company implements the marketing strategy of "basic medicine development", focusing on promoting the two exclusive basic medicine products of gynecological Qianjin tablets/capsules and Buxueyimu pills/granules.
Under the influence of the epidemic, the medical sector A certain share of growth has been maintained throughout the year.
It is worth mentioning that Gynecological Qianjin Tablets/Capsules have maintained the status of the first brand of oral gynecological inflammation Chinese patent medicine for more than ten consecutive years.
According to data from Mi Nei.
com, the market share of terminal gynecological Qianjin capsules in China's public medical institutions has steadily increased in recent years, and the market share will reach 3.
34% in 2020.
Qianjin Pharmaceutical pointed out in its annual report that the company’s products are mainly sold through medical terminals and retail terminals.
The medical marketing department has been established in the hospital terminal company to actively participate in national and provincial and municipal medical academic seminars to disseminate and exchange the company’s products.
The clinical research results enable professional doctors to understand, be familiar with and recognize the characteristics and efficacy of the company's products, thereby ensuring the clinical and rational use of the products, and ultimately transforming product advantages into market advantages.
With the advancement of the national basic medicine policy, the company implements the marketing strategy of "basic medicine development", focusing on promoting the two exclusive basic medicine products of gynecological Qianjin tablets/capsules and Buxueyimu pills/granules.
Under the influence of the epidemic, the medical sector A certain share of growth has been maintained throughout the year.
It is worth mentioning that Gynecological Qianjin Tablets/Capsules have maintained the status of the first brand of oral gynecological inflammation Chinese patent medicine for more than ten consecutive years.
The market share of Honghe Fujie Lotion and Kangfuyan Capsules in China's public medical institutions in recent years
Source: Terminal competition landscape of China's public medical institutions
According to data from Minai.
com, in 2020, the two exclusive products of Shandong Buchang Shenzhou Pharmaceutical, the terminal of China's public medical institutions, Honghe Fujie Lotion and Kangfuyan Capsules are both in the TOP10 products.
In recent years, Buchang Pharmaceuticals has focused on increasing the development of new products in the treatment of cardio-cerebrovascular, gynecology, diabetes and other major diseases.
Among them, it has continued to develop products such as Honghe Fujie Lotion and Kangfuyan Capsules.
Exploit the potential of existing products and extend the product life cycle.
com, in 2020, the two exclusive products of Shandong Buchang Shenzhou Pharmaceutical, the terminal of China's public medical institutions, Honghe Fujie Lotion and Kangfuyan Capsules are both in the TOP10 products.
In recent years, Buchang Pharmaceuticals has focused on increasing the development of new products in the treatment of cardio-cerebrovascular, gynecology, diabetes and other major diseases.
Among them, it has continued to develop products such as Honghe Fujie Lotion and Kangfuyan Capsules.
Exploit the potential of existing products and extend the product life cycle.
Kuntai Capsules and Zishen Yutai Pills grow against the trend
Kuntai Capsules and Zishen Yutai Pills grow against the trend Sales of Kuntai Capsules in Public Medical Institutions in China in Recent Years
Source: Terminal competition landscape of China's public medical institutions
Kuntai Capsule is an exclusive product of Guiyang Xintian Pharmaceutical.
It is a pure Chinese medicine patented product for the improvement of clinical symptoms related to "ovarian function decline" (including improvement of clinical symptoms related to menopausal syndrome).
According to data from Mi Nei.
com, the sales of Kuntai capsules in China's public medical institutions have grown steadily in recent years, with a year-on-year growth of 9.
09% in 2020, ranking it among the top 3 products.
Xintian Pharmaceutical said that Kuntai Capsule is one of the company's main varieties of rapid development in the future.
In addition, the company will further use its brand advantages to continuously strengthen the marketing of exclusive varieties such as Kuntai capsules and Sophora flavescens gel to expand market share; make full use of the company's industry advantages to continuously attract outstanding talents in scientific and technological innovation , and promote industrial and product innovation; At the same time, it takes advantage of the company's capital to actively carry out high-quality industry investment and mergers and acquisitions.
Through multiple measures to promote the continuous growth of the company's performance, and continuously improve the company's overall industry position and market competitiveness.
Talent Talent TalentIt is a pure Chinese medicine patented product for the improvement of clinical symptoms related to "ovarian function decline" (including improvement of clinical symptoms related to menopausal syndrome).
According to data from Mi Nei.
com, the sales of Kuntai capsules in China's public medical institutions have grown steadily in recent years, with a year-on-year growth of 9.
09% in 2020, ranking it among the top 3 products.
Xintian Pharmaceutical said that Kuntai Capsule is one of the company's main varieties of rapid development in the future.
In addition, the company will further use its brand advantages to continuously strengthen the marketing of exclusive varieties such as Kuntai capsules and Sophora flavescens gel to expand market share; make full use of the company's industry advantages to continuously attract outstanding talents in scientific and technological innovation , and promote industrial and product innovation; At the same time, it takes advantage of the company's capital to actively carry out high-quality industry investment and mergers and acquisitions.
Through multiple measures to promote the continuous growth of the company's performance, and continuously improve the company's overall industry position and market competitiveness.
Sales of Terminal Zishen Yutai Pills in China's Public Medical Institutions in Recent Years
Source: Terminal competition landscape of China's public medical institutions
Zishen Yutai Pills is an exclusive product of Guangzhou Baiyunshan Zhongyi Pharmaceutical.
It is used for slippery fetus caused by deficiency of both spleen and kidney and inconsistent treatment (prevention and treatment of habitual abortion and threatened abortion).
According to data from Mi Nei.
com, the sales of terminal Zishen Yutai pills in public medical institutions in China have grown rapidly in recent years.
In 2019, they increased by more than 80% year-on-year, and again by 8.
55% in 2020.
The market share has also risen from 1.
07% in 2018 to 2020.
2.
64% of the total.
Baiyunshan's analysis of the production and sales of main products in the 2020 annual report pointed out that the inventory of Zishen Yutai Pills increased significantly year-on-year, mainly due to the expected increase in product sales demand by the subordinate production enterprises , and the inventory was prepared in advance.
It is worth mentioning that the sales volume of Zishen Yutai Pills in 2019 increased by more than 60% year-on-year, mainly due to increased investment in product design, R&D and marketing in the early stage, and with the liberalization of the national two-child policy, products entered During the period of rapid development, the sales volume increased rapidly.
Enterprise business enterpriseIt is used for slippery fetus caused by deficiency of both spleen and kidney and inconsistent treatment (prevention and treatment of habitual abortion and threatened abortion).
According to data from Mi Nei.
com, the sales of terminal Zishen Yutai pills in public medical institutions in China have grown rapidly in recent years.
In 2019, they increased by more than 80% year-on-year, and again by 8.
55% in 2020.
The market share has also risen from 1.
07% in 2018 to 2020.
2.
64% of the total.
Baiyunshan's analysis of the production and sales of main products in the 2020 annual report pointed out that the inventory of Zishen Yutai Pills increased significantly year-on-year, mainly due to the expected increase in product sales demand by the subordinate production enterprises , and the inventory was prepared in advance.
It is worth mentioning that the sales volume of Zishen Yutai Pills in 2019 increased by more than 60% year-on-year, mainly due to increased investment in product design, R&D and marketing in the early stage, and with the liberalization of the national two-child policy, products entered During the period of rapid development, the sales volume increased rapidly.
Source: Mi Nei.
com database, announcement of listed companies
com database, announcement of listed companies
